Research Article
Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Table 1
Clinical characteristics of patients.
| | Variable | IMRT + sorafenib (n = 36) | IMRT (n = 46) | value | | n (%) | n (%) |
| | Gender | | | 0.362 | | Male | 31 (86.1) | 36 (78.3) | | | Female | 5 (13.9) | 10 (21.7) | | | Age | | | 0.328 | | ≤55 | 13 (36.1) | 12 (26.1) | | | >55 | 23 (63.9) | 34 (73.9) | | | Tumor size (cm) | | | 0.459 | | ≤5 | 14 (38.9) | 23 (50.0) | | | >5–≤10 | 16 (44.4) | 15 (32.6) | | | >10 | 6 (16.7) | 8 (17.4) | | | AJCC TNM stage | | | 0.236 | | III | 18 (50.0) | 29 (63.0) | | | IV | 18 (50.0) | 17 (37.0) | | | ECOG | | | 1.000 | | ≤1 | 32 (88.9) | 40 (87.0) | | | >1 | 4 (11.1) | 6 (13.0) | | | Etiology | | | 0.588 | | HBV | 30 (83.3) | 36 (78.3) | | | HCV | 2 (5.6) | 4 (8.7) | | | None HBV, none HCV | 4 (11.1) | 6 (13.0) | | | Antiviral therapy | | | 0.153 | | Yes | 18 (50.0) | 25 (54.3) | | | No | 18 (50.0) | 21 (45.7) | | | Child–Pugh classification | | | 1.000 | | A | 35 (97.2) | 44 (95.7) | | | B | 1 (2.8) | 2 (4.3) | | | ALT levels (IU/L) | | | 0.854 | | ≤40 | 30 (83.3) | 39 (84.8) | | | >40–≤100 | 5 (13.9) | 6 (13.0) | | | >100 | 1 (2.8) | 1 (2.2) | | | AFP levels (μg/L) | | | 0.390 | | ≤20 | 7 (19.4) | 15 (32.6) | | | 20–400 | 10 (27.8) | 9 (19.6) | | | ≥400 | 19 (52.8) | 22 (47.8) | | | PVTT typing | | | 0.544 | | II | 12 (33.3) | 13 (28.3) | | | III | 15 (41.7) | 29 (63.0) | | | IV | 9 (25.0) | 4 (8.7) | | | Radiation dose (Gy) | | | 0.120 | | ≤50 | 19 (52.8) | 32 (69.6) | | | >50 | 17 (47.2) | 14 (30.4) | |
|
|
IMRT, intensity-modulated radiotherapy; AJCC, American Joint Committee on Cancer; ECOG, eastern cooperative oncology group; HBV, hepatitis B virus; HCV, hepatitis C virus; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombosis.
|
